Gapping up
In reaction to earnings/guidance:
- TDC +27.4% (raises Q1 EPS guidance above consensus), XM +15.9%, HZO +8.9%, EFX +8%, CHDN +5.9%, POOL +5.8%, TSCO +5.4%, TAL +4.8%, RHI +4.5%, DFS +3.7%, T +3.6%, SLM +3.3%, CLB +3.3%, CLF +3.2%, IQV +3.2%, ALLE +2.9%, CP +2.7%, AAL +2.7%, BX +2.7%, SAVE +2.6%, PNR +2.6%, HBAN +2.5%, HCA +2.5%, LUV +2.4%, FAF +2.4%, KMI +2.2% (also increases dividend by 3%), UFPI +2.2%, TPH +2%, SON +2%, RS +2%, BW +1.8%, HRI +1.8%, LSTR +1.7%, WHR +1.7%, ALK +1.6%, DGX +1.5%, CMG +1.4%, MKTX +1.3%, DHI +1.2%, DHR +1.1%, GGG +1%
Other news:
- MVIS +8.2% (strength attributed to positive mentions on Reddit forums)
- XL +5% (announces partnership with Dickinson Fleet Services for expansion of nationwide service support)
- EBET +4.8% (announces its international consumer platform, Gogawi.com, is now accepting more than 30 different cryptocurrencies for deposits, including Dogecoin and Bitcoin)
- ATOS +4.7% (stock offering)
- RMBS +4.1% (announces the Rambus HBM2E memory interface subsystem)
- LDI +3.6% (announces $200 mln special dividend and early lock-up release)
- BXC +3.4% (CEO to retire)
- HZAC +2.6% (enters into merger agreement with Vivid Seats)
- CF +2.2% (signs engineering and procurement contract with thyssenkrupp)
- TEN +2.1% (Carl Icahn affirms lowered active stake following recent sale of ~133K shares)
- KMPH +1.9% (confirms receipt of $10 mln milestone payment for FDA approval of AZSTARYS)
- GBX +1.5% (CEO purchased 50K shares worth ~$2.2 mln)
- DVAX +1.2% (announces Valneva's initiation of Phase 3 trial for inactivated, COVID-19 vaccine candidate using Dynavax's CpG 1018 adjuvant)
- BALY +1.2% (issues response to City of Richmond's decision to remove BALY casino from selection process)
- DHI +1.2% (announces new $1 bln stock repurchase authorization)
- PLTR +0.9% (named as as a Crown Commercial Service supplier)
Analyst comments:
- F +2.4% (upgraded to Outperform from Peer Perform at Wolfe Research)
- ET +1.8% (upgraded to Outperform from In-line at Evercore ISI)
- AN +1.3% (upgraded to Buy from Hold at The Benchmark Company)